StockNews.AISignal intelligencePublic signal · 1-minute delayed
Source-backed market context you can read and share without an account.
Positive safety signals reduce clinical and regulatory risk for VXRT's platform; however, efficacy readouts remain years away (2027 main cohort). Government funding adds visibility and may improve financial flexibility, supporting a constructive sentiment but with limited near-term upside absent efficacy data.
What happened, with direct paths to the underlying reporting
Vaxart (VXRT) disclosed topline safety data from a 400-participant Phase 2b sentinel safety cohort comparing its oral pill COVID-19 vaccine with an approved mRNA vaccine. No vaccine-related SAEs or Grade 3+ AEs occurred in either arm over 12 months. Full results for the main cohort (~5,000 participants) are anticipated in 2027, backed by BARDA funding up to $344.8 million.
Transparent limits for an AI-generated research aid
StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.